JP4509999B2 - 医薬送達及び抗原提示システムとしてのペプチドナノ粒子 - Google Patents

医薬送達及び抗原提示システムとしてのペプチドナノ粒子 Download PDF

Info

Publication number
JP4509999B2
JP4509999B2 JP2006502449A JP2006502449A JP4509999B2 JP 4509999 B2 JP4509999 B2 JP 4509999B2 JP 2006502449 A JP2006502449 A JP 2006502449A JP 2006502449 A JP2006502449 A JP 2006502449A JP 4509999 B2 JP4509999 B2 JP 4509999B2
Authority
JP
Japan
Prior art keywords
peptide
nanoparticles
drug
nanoparticle
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006502449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519781A5 (https=
JP2006519781A (ja
Inventor
ブルクハルト，ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32864945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4509999(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2006519781A publication Critical patent/JP2006519781A/ja
Publication of JP2006519781A5 publication Critical patent/JP2006519781A5/ja
Application granted granted Critical
Publication of JP4509999B2 publication Critical patent/JP4509999B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006502449A 2003-02-17 2004-02-16 医薬送達及び抗原提示システムとしてのペプチドナノ粒子 Expired - Fee Related JP4509999B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003551 2003-02-17
PCT/IB2004/000423 WO2004071493A1 (en) 2003-02-17 2004-02-16 Peptidic nanoparticles as drug delivery and antigen display systems

Publications (3)

Publication Number Publication Date
JP2006519781A JP2006519781A (ja) 2006-08-31
JP2006519781A5 JP2006519781A5 (https=) 2007-03-29
JP4509999B2 true JP4509999B2 (ja) 2010-07-21

Family

ID=32864945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502449A Expired - Fee Related JP4509999B2 (ja) 2003-02-17 2004-02-16 医薬送達及び抗原提示システムとしてのペプチドナノ粒子

Country Status (6)

Country Link
US (1) US8575110B2 (https=)
EP (1) EP1594469B1 (https=)
JP (1) JP4509999B2 (https=)
AT (1) ATE371437T1 (https=)
DE (1) DE602004008582T2 (https=)
WO (1) WO2004071493A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US9079765B2 (en) * 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
MX2008015529A (es) 2006-06-12 2009-01-13 Cytos Biotechnology Ag Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8889117B2 (en) * 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2205256A4 (en) * 2007-09-26 2012-10-24 Dana Farber Cancer Inst Inc REAGENTS TO TRIGGER IMMUNE REACTION
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
RU2540871C2 (ru) * 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2313108A4 (en) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army MALARIA VACCINE FROM SELF-ORGANIZING POLYPEPTIDE NANOTEHICLES
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8580274B2 (en) 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
CA2762653A1 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN107617110A (zh) * 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
CN103221070B (zh) 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) * 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
CN104136454A (zh) 2011-10-12 2014-11-05 阿尔法-O肽股份公司 作为针对诺如病毒感染的疫苗的自装配肽纳米粒
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
TW201511774A (zh) * 2013-09-18 2015-04-01 Iner Aec Executive Yuan 放射性標誌之主動標靶性醫藥組合物及其用途
US10188136B2 (en) 2016-02-16 2019-01-29 Indian Institute Of Science Education And Research Hydrophobin mimics: process for preparation thereof
KR20190092472A (ko) * 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
KR101955928B1 (ko) * 2016-12-30 2019-03-08 경상대학교산학협력단 먹장어 유래 vlrb 단백질의 소수성 테일 도메인을 포함하는 다량체 다가 중합체
CA3054172A1 (en) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EA201991918A1 (ru) 2017-03-23 2020-05-15 Альфа-О Пептидс Аг Самосборные белковые наночастицы со встроенными белками с шестиспиральным пучком
US11213582B2 (en) 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
US20220362370A1 (en) * 2019-08-27 2022-11-17 Tokyo Institute Of Technology Composite protein monomer having non-structural protein of virus supported thereon, aggregate of composite protein monomer, and component vaccine comprising aggregate as active ingredient
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN111150842B (zh) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
EP3901261A1 (en) * 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
US20230355540A1 (en) 2020-09-29 2023-11-09 Oxford University Innovation Limited Stroke treatment
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
US20250042946A1 (en) 2021-12-08 2025-02-06 Oakgrove Bio Llc Biological Production of Histidine-Rich Peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US6756039B1 (en) * 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
EP1191836B1 (en) * 1999-06-25 2004-09-29 Leslie H. Kondejewski Polypeptide compositions formed using a coiled-coil template and methods of use
JP4085231B2 (ja) * 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法

Also Published As

Publication number Publication date
US8575110B2 (en) 2013-11-05
DE602004008582T2 (de) 2008-05-21
DE602004008582D1 (de) 2007-10-11
JP2006519781A (ja) 2006-08-31
EP1594469B1 (en) 2007-08-29
US20070014804A1 (en) 2007-01-18
WO2004071493A1 (en) 2004-08-26
ATE371437T1 (de) 2007-09-15
EP1594469A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
JP4509999B2 (ja) 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
Spicer et al. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Lee et al. Adaptations of nanoscale viruses and other protein cages for medical applications
JP5211109B2 (ja) 膜転位剤および製薬学的有効成分の複合物
ES2847288T3 (es) Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
Rohovie et al. Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery
JP6553105B2 (ja) クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
Koudelka et al. Virus-based nanoparticles as versatile nanomachines
US10513539B2 (en) Hydrophobic modified peptides and their use for liver specific targeting
ES2441118T3 (es) Péptidos modificados hidrófobos derivados de preS del virus de la hepatitis B (HBV), y su uso como inhibidores del acceso del HBV y el HDV
Le et al. Biodistribution of filamentous plant virus nanoparticles: pepino mosaic virus versus potato virus X
WO2009108822A1 (en) Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use
Yildiz et al. Engineering of Brome mosaic virus for biomedical applications
Lee et al. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery
ES2708662T3 (es) Péptidos hidrofóbicos modificados para el diagnóstico hepático específico
CN107029239A (zh) 一种多功能靶向分子及其用途
EP3145540B1 (en) Chemically activated nanocapsid functionalized for cancer targeting
CN109517843A (zh) 一种跨屏障靶向病灶的递药系统、载体系统及宿主细胞系统
Bajaj et al. Engineering virus capsids into biomedical delivery vehicles: structural engineering problems in nanoscale
Shaik et al. Artificial viruses: A nanotechnology based approach
JP2008162981A (ja) ビオチン化ないしホーミングペプチド提示型バイオナノカプセル
AU2024297005A1 (en) Compositions of pneumococcal antigens
Vuppu et al. Viral Vector–Based Nanoparticles
Kiong et al. Development of Multilayer Nanoparticles for the Delivery of Peptide-Based Subunit Vaccine against Group A Streptococcus. Pharmaceutics 2022, 14, 2151
CN117414440A (zh) 一种抗肿瘤的噬菌体-阿霉素复合物及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100406

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100428

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4509999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees